U.S. markets closed

Epigenomics AG (EPGNF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
3.0800+0.2800 (+10.00%)
At close: 3:25PM EST

Epigenomics AG

Geneststrasse 5
Berlin 10829
49 30 243 450

IndustryDiagnostics & Research
Full Time Employees38

Key Executives

NameTitlePayExercisedYear Born
Mr. Gregory HamiltonCEO & Member of the Exec. BoardN/AN/A1970
Mr. Albert WeberExec. VP of Fin. & Member of the Exec. BoardN/AN/A1963
Dr. Jorge A. GarcesAdvisorN/AN/A1972
Mr. Peter VogtVP of Corp. Communications & Investor RelationsN/AN/AN/A
Dr. Noel Thomas DohenyChief Exec. Officer of Epigenomics Inc.N/AN/AN/A
Frederic HilkeInvestor Relations OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, Asia, and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of cancers. In addition, the company engages in the identification of biomarker opportunities for various cancers, such as bladder cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Corporate Governance

Epigenomics AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.